Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.39 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 4/20 | 0.67 |
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | HTR2B | P41595 | 4/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329312 | 0.98 | PNMT (0.69) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL383414 | 0.95 | PNMT (0.67) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL16033643 | 0.93 | PNMT (0.64) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL532012 | 0.80 | PNMT (0.85) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL29543416 | 0.80 | ASIC3 (0.56) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL329775 | 0.80 | PNMT (1.00) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL29587836 | 0.80 | PNMT (1.00) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL947776 | 0.79 | PNMT (0.81) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL1124954 | 0.79 | PNMT (0.96) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL25207974 | 0.77 | PNMT (0.79) | PNMTHTR2CHTR2AHTR2BASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218869-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112166113-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| EP-2931721-B1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-9359345-B2 | Thiazole derivatives as inhibitors of Bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150353534-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2015-12-10 | — | — | US | disclosed |
| EP-2931721-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014090715-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | ADRB1 515/4885HTR1A 116/4885ADRA2A 964/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | ADRB1 731/4885HTR1A 298/4885ADRA2A 1464/4885 |
| US-20150353534-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | ADRB1 1396/4885HTR1A 4379/4885ADRA2A 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.